Please use this identifier to cite or link to this item:
https://doi.org/10.1371/journal.pone.0013452
Title: | The dopamine metabolite 3-methoxytyramine is a neuromodulator | Authors: | Sotnikova, T.D. Beaulieu, J.-M. Espinoza, S. Masri, B. Zhang, X. Salahpour, A. Barak, L.S. Caron, M.G. Gainetdinov, R.R. |
Issue Date: | 2010 | Citation: | Sotnikova, T.D., Beaulieu, J.-M., Espinoza, S., Masri, B., Zhang, X., Salahpour, A., Barak, L.S., Caron, M.G., Gainetdinov, R.R. (2010). The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS ONE 5 (10) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0013452 | Abstract: | Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3- methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. © 2010 Sotnikova et al. | Source Title: | PLoS ONE | URI: | http://scholarbank.nus.edu.sg/handle/10635/126556 | ISSN: | 19326203 | DOI: | 10.1371/journal.pone.0013452 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.